Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin versus intramuscular benzathine penicillin for secondary prevention of rheumatic heart disease in Nigerian secondary school students
PACTR202605528662643Not yet recruiting
- Sponsor
- Akintunde Adeseye Abiodun
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of azithromycin and Benzathine penicillin in rheumatic heart disease (RHD), sponsored by Akintunde Adeseye Abiodun. Primary endpoint: Progression to more advanced rheumatic heart disease. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
azithromycinBenzathine penicillin
03
Conditions
rheumatic heart disease (RHD)
Beyond the preview
Go deeper on PACTR202605528662643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605528662643.